Pierre Socha
Partner in the Early Stage Fund
Cambridge
Human
Bio
Pierre joined Amadeus in 2012 and is a Partner in the Early Stage Fund. His focus is on the Health and Bio sectors.
He led our investments in companies such as synthetic biology specialist ConstructiveBio, cell and gene therapy manufacturing platform OriBiotech, protein degradation leader PhoreMost, imaging biomarker specialist Quibim, advanced wound therapy leader Natrox, computer vision platform V7, Parkinson’s therapy developer Charco, and healthcare platform Doctify. He also oversees our investment in organ transplantation leader Organox.
Pierre is an operator turned investor. Prior to joining Amadeus, he was an entrepreneur with PE backed biotech Avesthagen where he joined the founding team in 2002 and helped grow the business over a decade. During his tenure, he oversaw the corporate strategy of the group and led its functional food division. Pierre started his career as an analyst at Natexis.
Pierre holds a MSc in Mathematics and Econometrics from Aix-Marseille University, France and graduated from executive programs at Stanford, MIT and Harvard.
Pierre is the contact for
-
HumanQuibim is a medtech company turning imaging data into predictive insights to drive precision medicine in oncology, neurology, and immunology.
Quibim
-
IntelligenceV7 builds Trustworthy AI systems that combine human insight with foundation models to deliver scalable, vision-powered automation across critical industries.
V7 Labs
-
HumanOri Biotech is a cell and gene therapy manufacturing company whose IRO® platform automates and accelerates production to make advanced therapies more scalable, affordable, and accessible.
Ori Biotech
-
HumanOrganOx is a medtech company pioneering normothermic liver perfusion with its metra device, improving transplant outcomes and increasing the use of donor organs worldwide.
OrganOx
-
HumanPhoreMost is a biotech company expanding the potential of targeted protein degradation through novel mini-protein engineering and proprietary platforms to develop next-generation degrader therapies.
PhoreMost
-
HumanNatrox® is an advanced wound care therapy developed in Cambridge that delivers continuous topical oxygen to accelerate healing in acute and chronic wounds.
Natrox
-
HumanDoctify is a healthtech platform providing SaaS tools and booking services that connect patients with private healthcare providers, making access to care faster, simpler, and more transparent.
Doctify
-
Human PlanetConstructive Bio is a synthetic biology company that rewrites genomes to create novel biomolecules, enabling next-generation materials and therapeutics beyond the limits of natural biology.
Constructive Bio
